You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic CancerONC212 Dampens Mitochondria in Pancreatic Cancer
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, June 2021
|
| DOI | 10.1158/1535-7163.mct-20-0962 |
| Pubmed ID | |
| Authors |
Isacco Ferrarini, Anna Louie, Lanlan Zhou, Wafik S. El-Deiry |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 46% |
| India | 1 | 8% |
| Brazil | 1 | 8% |
| Unknown | 5 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 46% |
| Scientists | 3 | 23% |
| Science communicators (journalists, bloggers, editors) | 2 | 15% |
| Practitioners (doctors, other healthcare professionals) | 2 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 18% |
| Unspecified | 2 | 9% |
| Other | 2 | 9% |
| Professor > Associate Professor | 2 | 9% |
| Student > Ph. D. Student | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 9 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 2 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
| Agricultural and Biological Sciences | 2 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Chemistry | 2 | 9% |
| Other | 2 | 9% |
| Unknown | 10 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 May 2023.
All research outputs
#6,365,268
of 25,775,807 outputs
Outputs from Molecular Cancer Therapeutics
#1,422
of 4,092 outputs
Outputs of similar age
#127,530
of 460,472 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#11
of 52 outputs
Altmetric has tracked 25,775,807 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,092 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 460,472 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.